Prostaglandin E2 Dinoprostone Antiphlogistic Raw Material Powder CAS 363-24-6 Drugs

Details:

Prostaglandin E2 Dinoprostone Antiphlogistic Raw Material Powder CAS 363-24-6 Drugs

Quick detail

1. Name: Dinoprostone
2. CAS No.: 363-24-6
3. Formula: C20H32O5
4. Molecular Weight: 352.47
5. Synonyms: 5-Heptenoicacid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]- (8CI);(-)-Prostaglandin E2;(15S)-Prostaglandin E2; Cervidil;Cerviprime;Dinoprostone;Enzaprost E;Minprositin E2;NSC 196514;PGE2;Primiprost;Prostaglandin E2;Prostenon;Prostenone;Prostin (prostaglandin);U 12062;l-Prostaglandin E2;
6. EINECS: 206-656-6
7. Density: 1.148 g/cm3
8. Melting Point: 66-68 °C
9. Boiling Point: 530.1 °C at 760 mmHg
10. Flash Point: 288.5 °C
11. Solubility: ethanol: 1 mg/mL
12. Appearance: white to pale yellowish-cream powder
13. Product Categories: Prostaglandins;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
14. alpha -85.5 º (c=1, C2H5OH)
15. storage temp. −20°C
16. solubility ethanol: 1 mg/mL
17. Water Solubility :insoluble

Dinoprostone Description

rostaglandin E2: One of the prostaglandins, a group of hormone-like substances that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation. Prostaglandin E2 (PGE-2) is released by blood vessel walls in response to infection or inflammation that acts on the brain to induce fever. The enzyme mPGES-1 is involved in the production of PGE2 and is an important "switch" for activating the fever response.

Drug Interactions

Oxytocic agents

May augment effect of other oxytocic agents; avoid concomitant use. For the sequential use of oxytocin following dinoprostone cervical gel administration, a dosing interval of 6 to 12 h is recommended. A dosing interval of at least 30 min is recommended for the sequential use of oxytocin following the removal of the dinoprostone vaginal insert.